Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

作者：Christian Barro, Pascal Benkert, Giulio Disanto, Charidimos Tsagkas, Michael Amann, Yvonne Naegelin, David Leppert, Claudio Gobbi, Cristina Granziera, Özgür Yaldizli, Zuzanna Michalak, Jens Wuerfel, Ludwig Kappos, Katrin Parmar, Jens Kühle · 发表于：Brain · 年份：2018 · DOI：10.1093/brain/awy154 · 被引用次数：549 · 研究领域：Multiple Sclerosis Research Studies、Amyotrophic Lateral Sclerosis Research、Skin and Cellular Biology Research

Neuro-axonal injury is a key factor in the development of permanent disability in multiple sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid marker reflecting neuro-axonal damage in this disease. We aimed at comparing serum neurofilament light chain levels in multiple sclerosis and healthy controls, to determine their association with measures of disease activity and their ability to predict future clinical worsening as well as brain and spinal cord volume loss. Neurofilament light chain was measured by single molecule array assay in 2183 serum samples collected as part of an ongoing cohort study from 259 patients with multiple sclerosis (189 relapsing and 70 progressive) and 259 healthy control subjects. Clinical assessment, serum sampling and MRI were done annually; median follow-up time was 6.5 years. Brain volumes were quantified by structural image evaluation using normalization of atrophy, and structural image evaluation using normalization of atrophy, cross-sectional, cervical spinal cord volumes using spinal cord image analyser (cordial). Results were analysed using ordinary linear regression models and generalized estimating equation modelling. Serum neurofilament light chain was higher in patients with a clinically isolated syndrome or relapsing remitting multiple sclerosis as well as in patients with secondary or primary progressive multiple sclerosis than in healthy controls (age adjusted P < 0.001 for both). Serum neurofi...